Asthma Free Forever

Asthma Free Forever

Get Instant Access

Letsou GV, et al. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppressin. Ann Thorac Surg 68(6):2044-2048, 1999. Waldrep JC, et al. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone diproprionate liposome aerosol. Chest 105(1):106-110, 1994.

Waldrep JC, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 111(2):316-323, 1997.

78. Batavia R, et al. The measurement of beclomethasone diproprionate entrapment in liposomes: a comparison of a microscope and an HPLC method. Int J Pharm 212(1):109-119, 2001.

79. Gonzqlez-Rothi RJ, et al. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 13(11):1699-1703, 1996.

80. Suarez S, et al. Effect of dose and release rate on pulmonary targeting of liposomal Triamcinolone acetonide phosphate. Pharm Res 15(3):461-465, 1998.

81. DiMatteo M, Reasor MJ. Modulation of silica-induced pulmonary toxicity by dexamethasone-containing liposomes. Toxicol Appl Pharmacol 142(2):411-421, 1997.

82. Suntrez ZE, Shek PN. Liposomes promote pulmonaryglucocorticoid delivery. J Drug Target 6(3):175-182, 1998.

83. Hvizdos KM, Jarvis B. Budesonid inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 60(5):1141-1178, 2000.

84. Shapiro G, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 102(5):789-796, 1998.

85. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 104(4 Pt 2):200-209, 1999.

86. Szefler SJ. Meeting needs of infants and young children with asthma: new developments in nebulized corticosteroid therapy. Introduction. J Allergy Clin Immunol 104(4 Pt 2):159-161, 1999.

87. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 9(1):111 -122, 1996.

88. Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med 3(2):170-174, 1997.

89. Barrow WW. Treatment of mycobacterial infections. Rev Sci Tech 20(1):55-70, 2001.

90. Petty HR, McConnell HM. Cytochemical study of liposome and lipid vesicle phagocytosis. Biochim Biophys Acta 735(1):77-85, 1983.

91. Pedroso de Lima MC, et al. Interaction of antimycobacterial and anti-pneumocystis drugs with phospholipid membrances. Chem Phys Lipids 53(4):361-371, 1990.

92. Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B Desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposiiton in rats. J Pharm Pharmacol 52(6):619-627, 2000.

93. Purcell IF, Corris PA. Use of nebulized liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 50(12):1312-1323, 1995.

94. Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 12(3):229-246, 1995.

95. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 3(2):234-258, 2000.

96. Bartus RT, et al. Sustained delivery of proteins for novel therapeutic agents. Science 281(5380):1161-1162, 1998.

97. Cleland JL. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines. Biotechnol Prog 14(1):102-107, 1998.

98. Watts PJ, Davies MC, Melia CD. Microencapsulation using emulsification/solvent evaporation: an overview of techniques and applications. Crit Rev Ther Drug Carrier Syst 7(3):235-259, 1990.

99. Haghpanah M, Marriott C, Martin GP. Potential use of microencapsulation for sustained drug delivery to the respiratory tract. J Aerosl Med 7(2):185-188, 1994.

100. Todisco T, et al. Fate of human albumin micropshere and spherocyte radioaerosols in the human tracheobronchial tree. Lung 168, 665-671, 1990.

101. Bot AI, et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 17(3):275-283, 2000.

102. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 17(8):955- 961, 2000.

103. Narayan P, Marchant D, Wheatley MA. Optimization of spray drying by factorial design for production of hollow microspheres for ultrasound imaging. J Biomed Mater Res 56(3):333-341, 2001.

104. Martin C, Winet H, Bao JY. Acidity near eroding polylactide-polyglycolide in vitro and in vivo in rabbit tibial bone chambers. Biomaterials 17(24):2373-2380, 1996.

105. Fu K, et al. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 17(1):100-106, 2000.

106. Tang G, et al. Polyethylene glycol-conjugated superoxide dismutase projects rats against oxygen toxicity. J Appl Physiol 74(3):1425-1431, 1993.

107. Niven RW, et al. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 12(9):1343-1349, 1995.

108. Lang GM, et al. Potential therapeutic efficacy of allergen-monomethoxypolyethyl-ene glycol conjugates for in vivo inactivation of sensitized mast cells responsible for common allergies and asthma. Int Arch Allergy Immunol 113(1-3):58-60, 1997.

109. Klonne DR, et al. Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug Chem Toxicol 12(1):39-48, 1989.

110. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 12(2-3):151-231, 1995.

111. Li S, et al. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J Pharm Sci 85(8):873-877, 1996.

112. Dubost DC, et al. Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapetide. A novel example of an excipient-induced oxidation. Pharm Res 13(12):1811 -1814, 1996.

113. Crapo JD, et al. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 126(2):332-337, 1982.

114. Nicholas TE. Pulmonary surfactant: no mere paint on the alveolar wall. Respirology 1(4):247-257, 1996.

115. Jeffery PK, Li D. Airway mucosa: secretory cells, mucus and mucin genes. EurRespir J 10(7):1655-1662, 1997.

116. Widdicombe JG. Airway liquid: a barrier to drug diffusion? Eur Respir J 10(10):2194-2197, 1997.

117. Rubin BK. Therapeutic aerosols and airway secretions. J Aerosol Med 9(1):123-130, 1996.

118. McConville JT, et al. Use of a novel modified TSI for the evaluation of controlled-release aerosol formulations. I. Drug Dev Ind Pharm 26(11):1191-1198, 2000.

119. Niven, R.W. Engineering and testing of dry powders for inhalation therapy. In: International Society of Aerosols in Medicine. ISAM: Vienna, Austria, 1999.

120. Tyler WS, Julian MD. Gross and subgross anatomy of the lungs, pleura, connective tissue septa, distal airways, and structural units. In: Comparative Biology of the Normal Lung, Parent RA, ed. CRC Press: Boca Raton, FL, 1991, pp. 37-48.

Was this article helpful?

0 0
Allergy Relief

Allergy Relief

Have you ever wondered how to fight allergies? Here are some useful information on allergies and how to relief its effects. This is the most comprehensive report on allergy relief you will ever read.

Get My Free Ebook

Post a comment